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The clinical outcome of colorectal cancer (CRC) is associated with the immune response; 
thus, these tumors could be responsive to different immune therapy approaches. Natural 
killer (NK) cells are key antitumor primary effectors that can eliminate CRC cells without 
prior immunization. We previously determined that NK cells from the local tumor environ-
ment of CRC tumors display a profoundly altered phenotype compared with circulating 
NK cells from healthy donors (HD). In this study, we evaluated peripheral blood NK cells 
from untreated patients and their possible role in metastasis progression. We observed 
profound deregulation in receptor expression even in early stages of disease compared 
with HD. CRC-NK cells displayed underexpression of CD16, NKG2D, DNAM-1, CD161, 
NKp46, and NKp30 activating receptors, while inhibitory receptors CD85j and NKG2A 
were overexpressed. This inhibited phenotype affected cytotoxic functionality against 
CRC cells and interferon-γ production. We also determined that NKp30 and NKp46 are 
the key receptors involved in detriment of CRC-NK cells’ antitumor activity. Moreover, 
NKp46 expression correlated with relapse-free survival of CRC patients with a maximum 
follow-up of 71 months. CRC-NK cells also exhibited altered antibody-dependent cellu-
lar cytotoxicity function responding poorly to cetuximab. IL-2 and IL-15 in combination 
with cetuximab stimulated NK cell, improving cytotoxicity. These results show potential 
strategies to enhance CRC-NK cell activity.
Keywords: natural killer cells, colorectal cancer, nKp46, nKp30, cetuximab, il-2, il-15
Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; CRC, colorectal cancer; CRC-NK, peripheral blood NK cells 
from colorectal cancer patients; EGFR, epidermal growth factor receptor; HD, healthy donors; HD-NK, peripheral blood NK 
cells from healthy donors; IFN-γ, interferon-γ; NCR, natural cytotoxicity receptors; PB, peripheral blood; PBMC, peripheral 
blood mononuclear cells; PFS, progression-free survival; RFS, relapse-free survival; TNF-α, tumor-necrosis factor-α.
TaBle 1 | clinical and histological characteristics of crc patients.
Patients characteristics
Gender Male 26
Female 26
Age <50 10
≥50 42
Localization Right/trasversum colon 12
Left colon 28
Rectum 12
Stage I 8
II 23
III 13
IV 8
Histological grade Well differentiated 43
Poorly differentiated 9
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inTrODUcTiOn
Colorectal cancer (CRC) is the second leading cause of cancer 
mortality in the U.S., with approximately 143,000 new cases 
and 51,000 deaths expected by year (1). From the diagnosis of 
stage I and II cases, surgical resection is considered the mainstay 
treatment, with a 5-year survival rate of 80% (2). The standard 
management of advanced CRC has historically focused on multi-
agent chemotherapy. More recently, development of monoclonal 
antibodies (mAbs) that target VEGF (bevacizumab) and EGFR 
(cetuximab) led to their application in metastatic patients (stage 
IV) (3–5). Still, 70% of relapsed patients have a life expectancy of 
less than 2 years, as they do not respond to conventional therapy 
(6). Unlike conventional chemotherapies and targeted anticancer 
agents, which act directly on malignant cells or proximal stromal 
cells, immunotherapies have an indirect mechanism of action (7). 
It is clear that besides melanoma and renal cell carcinoma, tradi-
tionally considered immunologic targets, other solid tumors can 
also be immunologically responsive. Thus, the immune response 
in CRC is associated with clinical outcome (8), and it is known 
that CRC cells remain susceptible to T-cell-mediated killing 
despite prior exposure to chemotherapy (9). Innate immunity 
is involved in tumor immunosurveillance, and cytotoxic natural 
killer (NK) cells play an important role in the immune response 
to cancer by recognizing and killing a wide variety of tumor cells 
with reduced or absent MHC-class I expression or the expression 
of stress-induced molecules (10).
Natural killer cells exert direct cytotoxicity through perforin 
and granzyme exocytosis and by engagement of death receptors. 
NK cells also regulate the immune response by cytokine produc-
tion such as interferon-γ (IFN-γ) or tumor-necrosis factor-α 
(TNF-α) (11–13). NK cell activation is controlled by a dynamic 
balance between the positive and negative signals trigged by both 
activating and inhibitory receptors, correspondingly (10–12, 14, 
15). In the activating group, NKp30, NKp44 and NKp46 natural 
cytotoxicity receptors (NCR), NKG2D, DNAM-1, CD161, and 
CD16 receptors favor cytotoxicity and/or the production of 
cytokines. In the second group, NKG2A, CD85j, and CD158b 
receptors provide suppression signals by inhibition of stimulatory 
pathway (13, 16, 17). Recent evidence suggests that NK cells may 
also shape the adaptive immune response toward a T helper 1 
(Th1) profile, which is thought to be a key component in antitu-
mor responses (18, 19). However, NK cell efficacy against human 
solid tumors remains questionable, possibly due to the tumor 
microenvironment which suppresses the availability of fully com-
petent NK cells at the tumor site (20). We previously determined 
that NK cells from CRC patients displayed multiple alterations in 
their phenotype with a drastic reduction in the expression of NK 
cell-activating receptors (21). Similarly, peripheral blood (PB) 
analysis revealed NK cells dysfunction with reduced expression 
of activating receptors (22) and recently Hou et  al. (23) deter-
mined that the intracellular IFN-γ production and degranulation 
activity of NK cells in patients with CRC were significantly lower 
than the one in healthy adults.
In the present work, we evaluated PB NK cells from untreated 
CRC patients, and found a significant dysregulation in patients 
from all clinical stages, including those with limited disease that 
affects functionality against CRC cells. More precisely, NKp30 
and NKp46 were the main receptors involved in CRC-NK cell 
inhibition of antitumor activity. Moreover, the downregulation 
of NKp46 receptor expression correlated with lower relapse-free 
survival (RFS) of CRC patients with a maximum follow-up of 
71  months. CRC-NK cells also exhibited altered antibody-
dependent cellular cytotoxicity (ADCC) function responding 
poorly to cetuximab, which in addition to inhibiting the prolifera-
tion of K-RAS wild-type tumor cells (24), mediates ADCC per-
formed by NK cells through CD16 Fcγ receptor, which has been 
strongly associated to cetuximab response in CRC (25). Finally, in 
order to reactivate CRC-NK cells, we assayed the combination of 
IL-2 and IL-15 cytokines with cetuximab resulting in an in vitro 
improved antitumor activity.
MaTerials anD MeThODs
Patient samples
The present study was approved by the Institutional Ethics 
Committee of the Instituto Alexander Fleming (IAF), and all 
patients enrolled provided written-informed consent. Samples 
were obtained from 52 patients (AJCC stages I–IV) without any 
other concomitant colorectal disease who underwent surgical 
resection of CRC at the Surgery Service of the IAF (Table  1). 
Inclusion criteria: written-informed consent, age ≥18 years old, 
and available blood sample collected at the moment of surgery. 
Exclusion criteria: exposure to chemotherapy and/or lack of writ-
ten consent. As blood samples were limited in some cases, some 
determinations could not be performed for all patients. Nine of 
them where only assayed for TGF-β measurement, and func-
tional assays were performed in a reduced number of samples. 
As controls, PB samples were obtained from healthy donors (HD) 
at the Hemotherapy Service of the IAF.
collection of samples and nK cell 
isolation
Peripheral blood samples from CRC patients (3–15 ml each) and 
HD were obtained in heparinized collection tubes. PB mono-
nuclear cells (PBMC) were isolated by Ficoll-Paque PLUS (GE 
Healthcare Bio-Sciences AB) density gradient centrifugation. For 
xCELLigence assay, NK cells were purified by negative immune 
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selection using the NK selection kit (Miltenyi Biotech), follow-
ing company instructions. Purified NK cells (0.5–1.6  ×  106/
ml) were cultured in RPMI 1640 medium (GIBCO Invitrogen) 
supplemented with IL-2 (1000 IU/ml; Miltenyi Biotech) and 10% 
human serum AB (Biowest) for 2 days.
cell lines
The colon carcinoma cell line DLD-1 (ATCC) was maintained in 
Dulbecco’s modified eagle medium (DMEM, Invitrogen) supple-
mented with 10% heat-inactivated fetal calf serum (FCS) Natocor, 
2  mM l-glutamine, 3.5  mg/ml sodium bicarbonate, 4.5  mg/
ml glucose, and 1% Penicillin–Streptomycin (Invitrogen). The 
leukemic cell line K562 (ATCC) was maintained in RPMI 1640 
supplemented with 10% FCS and 1% Penicillin–Streptomycin.
cD107a Degranulation and iFn-γ 
secretion assays
Approximately 106 PBMC were cultured at 10:1 effector/target 
(E:T) ratio for 6 h at 37°C with K562 cells and incubated with 
anti-CD107a-FITC. After 1 h, protein transport inhibitor (Golgi 
Stop-BD) was added. Five hours later, cells were labeled in PBS 
for 30  min at 4°C with anti-CD56-APC and anti-CD3-PerCP, 
after that, cells were fixed and permeabilized (Cytofix/Cytoperm, 
BD Biosciences) and washed (Perm/Wash, BD Biosciences). 
Finally, cells were labeled in Perm/Wash buffer for 30  min at 
4°C with anti-IFN-γ-PE (BD Biosciences) and then collected on 
a FACSCalibur flow cytometer. The results are expressed as the 
percentage of IFN-γ+ or CD107a+ gated on NK cells. Spontaneous 
basal IFN-γ secretion and degranulation were determined in 
absence of targets and cytokines.
lysis and aDcc experiments
DLD-1 cells were used as target and labeled with Calcein-
acetyoxymethyl (Calcein-AM; Molecular Probes, Invitrogen Life 
Technology). The effector cells were PBMC, normalized by per-
centage of NK cells. The cytotoxicity assay was performed at 2.5:1 
E:T ratio, in triplicate, with 1 μg/ml of cetuximab or control mAb 
(rituximab). Three replicate wells for spontaneous (only target cells 
in RPMI medium with 10% FCS) and maximum release (only tar-
get cells in medium plus 1% Triton X-100) were measured. After 
incubation at 37°C in 5%CO2 for 4 h, supernatants were analyzed 
by fluorimetry (OPTIMA-BMG Labtech) to measure cell death 
(Calcein release), and the percentage of specific lysis was calcu-
lated as: (experimental fluorescence−spontaneous fluorescence)/
(maximum fluorescence−spontaneous fluorescence) × 100.
xcelligence assays
Natural killer cell-mediated lysis of DLD-1 cells was assessed by 
xCELLigence System (Roche), a label-free real-time monitoring 
assay of adherent cell lysis (26). It measures electrical impedance 
across interdigitated micro-electrodes integrated on the bottom 
of tissue culture E-Plates. The electrode impedance, which is 
recorded as a dimensionless parameter denominated cell index 
(CI) value, provides quantitative information about the status of 
the adherent cells, including cell number, viability, and morphol-
ogy. DLD-1 targets (15,000 cells) were seeded into the wells of 
96 E-Plates in 100 μl of RPMI 1640 medium plus 10% human 
serum and their adhesion was monitored for 5 h. IL-2-activated 
purified NK cells were added in a volume of 50 μl/well at 1:1 E:T 
ratio. Cocultures were assessed by the system with a measure-
ment of CI every 15 min for up to 300 min. Results expressed 
as CI, were normalized with RTCA Software (Roche, Applied 
Science, Mannheim, Germany) (nCI) and are expressed as % 
specific lysis:% lysis =  (nCI (no effector) − nCI (effector))/nCi 
(no effector) × 100. In some cocultures, NK cells were pretreated 
with anti-NKp46, anti-NKp30, anti-NKG2D, or anti-DNAM-1 
mAbs (R&D System).
Flow cytometry
Direct immunofluorescence was performed on PBMC or NK 
cells using specific mAbs and isotype-matched mAbs. Cells 
were washed with PBS and stained for 30 min at 4°C. NK cells, 
gated on CD3−CD56+ cells in the lymphocyte FSC/SSC subset 
were analyzed for the expression of CD16, NKp46, NKp30, 
NKp44, NKG2D, DNAM-1, CD161, CD94, CD8, NKG2A, 
CD85j, CD158a, and CD158b (PE-conjugated antibodies, BD 
Biosciences). mAbs and respective clones are listed in Table S1 in 
Supplementary Material. Cells were collected on a FACSCalibur 
flow cytometer (BD Biosciences). These data were analyzed using 
FlowJo software.
elisa
Plasma samples were tested for the presence of HLA-E and 
HLA-G soluble molecules by home-made ELISA tests. TGF-β 
content in human plasma was evaluated using a human TGF-β 1 
ELISA kit (BD) following the manufacturer’s instructions.
cytokines and lenalidomide Treatment
Natural killer cells were incubated overnight in medium supple-
mented with rhIL-2 1000 IU/ml, rhIL-15 10 ng/ml, or lenalido-
mide 10 μM (LC Laboratories) prior to performing degranulation, 
IFN-γ release, lysis, and ADCC, as described above.
statistical analysis
Comparisons between CRC patients and HD groups were assessed 
by non-parametric Mann–Whitney test when samples did not 
present normal distribution or parametric t-test, when samples 
presented normal distribution. For functional assays, we used 
paired t-test to compare different in vitro treatment conditions. 
Correlations were analyzed by Pearson (when samples presented 
normal distribution) or Spearman tests (in case of samples not 
normally distributed). The survival curves were plotted according 
to the Kaplan–Meier method and compared using the Log-rank 
test (p values <0.05 noted as *, p < 0.01 as ** and p < 0.001 as ***).
resUlTs
crc Patients showed altered Proportions 
of nK cells and Phenotypic abnormalities
In an observational and exploratory study, 52 CRC patients were 
enrolled, 34 from I–II stages without lymph node invasion and 18 
from stages III–IV with lymph node or metastatic dissemination. 
FigUre 1 | Proportions, absolute numbers, and phenotype of peripheral blood nK cells from crc patients. (a) Left: NK proportions in lymphocytes 
population of CRC patients (n = 43) and healthy donors (n = 52). Each symbol corresponds to different samples. For statistical analysis unpaired t-test was used. 
Middle: CRC-NK proportions in patients at different stages of the disease. Linear trend by one-way ANOVA test (p < 0.05). Right: distribution of CRC-NK absolute 
numbers expressed as 103/mm3 (n = 25). Linear trend by one-way ANOVA test (p < 0.05). (B) Expression of NK cell receptors. Activating and inhibitory receptor 
expression by peripheral blood NK cells from CRC patients of early (I–II) and late (III–IV) stages compared with healthy donors. For statistical analysis unpaired t-test 
or Mann–Whitney test were used. Horizontal bar represents mean value. *p < 0.05; **p < 0.01; ***p < 0.001. (c) Positive correlations between activating receptor 
expression in peripheral blood NK cells from CRC patients. Correlations between different receptor expressions were performed with Spearman or Pearson test. 
Regression coefficients r and p values on each graph.
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Fifty-two HD were analyzed as reference. The clinical character-
istics of patients are summarized in Table 1. Phenotypic analysis 
from CRC patients (43/52) displayed a significant increase of 
PB CRC-NK cell proportions among the lymphocyte subset as 
compared with HD (p <  0.001) (Figure  1A, left panel). Since 
mean age was significantly higher in the group of CRC patients 
(61.4 ± 12.0 vs. 38.0 ± 13.0 in HD, p < 0.0001), a linear regression 
model was developed using the percentage of NK cells as the 
outcome variable, and the presence of cancer and age as regres-
sive variables. The presence of cancer increases by 5.29% the 
amount of NK cells after adjusting by age (IC95 = 1.004–9.579, 
p =  0,016). Surprisingly, CRC-NK percentages were increased 
from stage II, reaching progressively the highest values in stage 
IV (linear trend ANOVA, p = 0.0122) (Figure 1A, middle panel). 
5Rocca et al. NK Cells in Colorectal Cancer Patients
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We also found higher absolute numbers of PB CRC-NK cells from 
available blood cell counts prior to surgery (25/43) (Figure 1A, 
right panel). CD56dim percentages in CRC-NK cells were similar 
to HD-NK cells (%CD56dim CRC-NK 93.06 ±  6.24 N =  43 vs. 
%CD56dim HD-NK 91.48 ± 5.01 N = 52). We, then, studied NK 
cell ex vivo phenotype according to the gating strategy depicted 
in Figure S1 in Supplementary Material. Most of the 13 NK 
cell receptors analyzed showed high inter-individual variability 
in CRC patients. Moreover, eight of these receptors presented 
modified expression in CRC patients compared with donors 
NK cells. Furthermore, the altered phenotypic expression was 
evident in CRC-NK from early stages of the disease (Figure 1B). 
The percentages of most activating receptors, NKG2D, DNAM-1, 
CD161, and NKp46 were decreased from non-metastatic stages 
(p <  0.001, p <  0.001, p <  0.001; and p <  0.01, respectively), 
while NKp30 presented diminished expression only in advanced 
ones (p < 0.001). The inhibitory receptors, CD85j and NKG2A 
were augmented from stages I–II (p <  0.001), while the KIRs 
2DL1/2DS1 recognized by anti-CD158a (27) was also dimin-
ished in early stages (p <  0.01). Expression of CD16, NKp44, 
CD94, CD158b (that encompasses KIR2DL2/2DL3/2DS2) (27), 
and CD8 were comparable to values observed in HD-NK cells 
(data not shown). Significant positive correlations were found 
between different activating receptors, including NKG2D, 
DNAM-1, NKp30, NKp46, and CD161, confirming the broadly 
phenotypic imbalance in CRC-NK (Figure 1C). In HD-NK cells, 
activating receptors displayed high and homogeneous percent-
ages that limited correlations mainly to the NCR group and 
CD16 (data not shown).
Based on the association between NK cell percentages and 
clinical stage, we investigated the involvement of other clinical 
features in NK cell receptor expression, as displayed by CRC 
patients. NK cells from patients with poorly differentiated 
tumors, considered of bad prognosis, highly expressed NKG2D 
and DNAM-1 activating receptors (p < 0.05 in both cases) and 
also higher expression of CD94 (p < 0.05). This receptor, which 
conforms the heterodimer CD94-NKG2A or CD94-NKG2C, was 
also regularly expressed in CRC-NK from patients with elevated 
carcino-embryonic antigen (CEA) values, associated as well with 
poor prognosis. Moreover, NKG2A and CD8 expression were 
diminished (p < 0.05 and p < 0.01, respectively) in patients with 
positive lymphatic vascular invasion (LVI), that is a strong bad 
prognostic marker and taken into account in treatment deter-
mination for stage II–III patients (Table S2 in Supplementary 
Material).
crc-nK exert Defective Functionality
Based on the phenotypic alterations of CRC-NK cells, we assayed 
the NK cell degranulation potential (CD107a surface expression) 
and IFN-γ production in response to challenge by K562 cells 
as canonical target. Freshly isolated PBMC, either incubated in 
medium or stimulated overnight with IL-2, were then cultivated 
with K562 cells for 6  h before analysis by flow cytometry (see 
Materials and Methods). Challenge with K562 cells led to CD107a 
expression in HD-NK cells, while NK cells from several patients 
kept their values close to spontaneous degranulation (Figure 2A, 
left panel). IL-2 pre-stimulated NK cells from HD and patients 
exhibited significantly augmented responsiveness (p < 0.001 in 
both cases). Still, CD107a expression levels of CRC-NK cells 
were lower than those achieved by HD-NK cells (p < 0.001 for 
both un-stimulated and stimulated NK cells) (Figure 2A, middle 
panel). Corresponding to phenotype alterations, diminished 
degranulation activity was detected in CRC patients at stages I–II 
showing an early immune impact on NK cells (Figure 2A, right 
panel).
Natural killer cells’ antitumor effects also implicate the pro-
duction of cytokines, such as IFN-γ. In this regard, culture with 
K562 did not induce significant levels of IFN-γ production on 
resting NK cells (Figure  2B, left panel). IL-2-pre-stimulation 
enhanced significantly the levels of IFN-γ production by HD-NK 
and in a lower extent by CRC-NK cells (p < 0.001) (Figure 2B, left 
and middle panel). Once again, the low functional capacity was 
observed since early stages of disease (Figure 2B, right panel).
lytic activity against crc cells is 
reduced in crc-nK
In order to evaluate NK cell cytotoxic capacity against CRC cells, 
we performed lysis assays of CRC cell line DLD-1 by HD and 
CRC-NK cells, using colorimetric calcein release test. CRC-NK 
also presented lower lytic capacity against DLD-1 since early stages 
of disease (Figure 3A), as we could anticipate from degranulation 
experiments (Figure 2). In addition, we observed an association 
between NK cell function, IFN-γ production, and lysis capacity 
in response to DLD-1 stimulation (p < 0.05) (Figure 3B). Even 
though IL-2- or IL-15-activated CRC-NK cells improved their 
lytic activity against CRC cells, they could still not reach HD-NK 
lytic ability (Figure 3C).
nKp46 and nKp30 expression is involved 
in reduced crc-nK Functionality
Correlation analyses were performed in order to establish which 
of the receptor abnormalities in CRC-NK play a major impact on 
the low-lytic activity against CRC cells. Expression levels of acti-
vating NCR NKp30 and NKp46, were positively correlated with 
DLD-1 cells lysis (r = 0.7364, p = 0.098; r = 0.9286, p = 0.0025; 
respectively) (Figure 4A). These associations were not present in 
HD-NK, mainly because HD exhibit homogeneous high expres-
sion of activating receptors and homogeneous low expression of 
the inhibitory ones (Figure 1B).
To elucidate the impact of these receptors in CRC cells cyto-
toxicity, we assessed the lysis of DLD-1 cells by purified IL-2-
activated HD-NK cells using a dynamic assay that quantifies the 
CI of adherent targets. The lytic activity of NK cells provoked the 
detachment/apoptosis of CRC cells, as evidenced by an abrupt 
decay of CI after the addition of effectors (Figure  4B, upper 
panel). From the CI values, lysis curves were calculated. In some 
experiments, receptor-neutralizing mAbs, previously tested 
to block NKp46, NKp30, NKG2D, and DNAM-1 receptors in 
melanoma (28) and renal carcinoma (29) were used (Figure 4B, 
middle panel). Separate addition of anti-NKp46, anti-DNAM-1, 
or anti-NKG2D mAbs decreased CRC cell lysis; the addition of 
anti-NKp30 mAb induced the highest percentage of inhibition 
(35.70 ±  4.95%). Addition of anti-DNAM-1 and anti-NKG2D 
FigUre 2 | Peripheral blood crc-nK cells exhibit defective functionality. (a) NK cell degranulation capacity. Left: degranulation by HD (black) and CRC 
patient (red) NK cells stimulated by K562 with (lower) or without IL-2 pre-activation (upper). Comparisons were analyzed by paired t-test. Middle: %CD107a+ NK 
cells from HD and CRC patients pre-stimulated or not with IL-2 (n = 13). Right: degranulation by IL-2 pre-stimulated NK cells from HD or CRC patients according to 
early (I–II) and late (III–IV) stages. Comparison of NK cell function between donors and patients were analyzed by non-parametric Mann–Whitney test. (B) IFN-γ 
production by NK cells. Left: IFN-γ secretion by HD-NK (black) and CRC-NK cells (red) NK cells stimulated by K562 with (lower) or without IL-2 pre-activation 
(upper). Comparisons were analyzed by paired t-test. Middle: percentages of IFN-γ+ NK cells from HD and CRC patients, pre-stimulated or not with IL-2 (n = 13). 
Right: IL-2-pre-stimulated NK cells from HD and CRC patients according to early (I–II) and late (III–IV) stages. Comparison of NK cell function between donors and 
patients were analyzed by non-parametric Mann–Whitney test. Horizontal bar represents mean value. *p < 0.05; **p < 0.01; ***p < 0.001.
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mAbs slightly synergized when combined with anti-NKp30 
(Figure 4B, middle panel). These data indicate that the lysis of 
DLD-1 cells by IL-2-activated NK cells is mediated mainly by 
NKp30 (Figure 4B, lower panel) with the contribution of NKp46, 
NKG2D, and DNAM-1.
soluble TgF-β is augmented in crc 
Patients
Several soluble molecules were associated with receptor expres-
sion modulation and the impairment of NK cell activity (30, 31). 
To determine whether CRC patients presented augmentation 
FigUre 3 | lytic activity against crc cells is reduced in crc-nK 
cells. (a) Lysis percentage by CRC-NK (n = 17) and HD-NK (n = 16) cells 
measured by calcein release test. DLD-1 tumor cells were used as target at 
an E:T ratio of 2.5:1. Patients were divided in early (I–II) or late (III–IV) stages. 
(B) Positive correlation between functional activities of NK cells from CRC 
patients, lysis capacity, and IFN-γ production. (c) Lysis percentage of DLD-1 
cells by CRC-NK and HD-NK pre-stimulated by IL-2 or IL-15. Horizontal bar 
represents mean value. *p < 0.05; **p < 0.01; ***p < 0.001.
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of NK cell suppressive molecules, we performed ELISA assays 
from plasma patients. Soluble HLA-E molecules (>5 pg/ml) were 
detected in 7/35 patients (mean 22.9 ± 53.4; range 0–187.4 pg/
ml), and soluble HLA-G molecules (>5 ng/ml) were detected in 
the plasma of 6/43 patients (mean 1.8 ± 5.1; range 0–23.0 ng/ml). 
Non-significant differences were found as compared with plasma 
samples from HD (data not shown). However, the amount of total 
circulating TGF-β in the plasma of CRC patients, both early and 
late stages, was almost fivefold higher than in HD (Figure  5). 
Even when analyzed samples belonged to other CRC patient 
than those analyzed in functional assays, the increment of TGF-β 
production by CRC tumors could impact on NK cell phenotype 
and their respective functionality (32).
nKp46 expression is correlated with 
relapse-Free survival of crc Patients
Taking into account that deregulation of NK cell receptor 
expression was associated with function detriment, we ana-
lyzed if the exhausted phenotype had a correlation with clinical 
outcomes in a retrospective study. Patients were followed for 
a median of 24.7 months and during this period 11/52 (21%) 
relapsed. As expected, clinical staging IV at diagnosis impacted 
on RFS (Figure 6A), while stage I, II, and III outcomes did not 
differ significantly. Considering that several receptors were 
underexpressed since early stages, we evaluated their expres-
sion in stages I, II, and III population (with the exclusion of 
stage IV patients) and correlate it with RFS. The patients were 
divided into groups of low and high NK cell receptor expres-
sion, using the median percentage value of each receptor as a 
cut-off. We found that expression of NKp46-activating receptor 
impacted on RFS by significant dissociation of Kaplan–Meier 
curves (p = 0.0261) (Figure 6B). Within stage IV, 100% (5/5) 
of patients progressed, independently of NKp46 status; never-
theless, it could be further analyzed if receptor expression had 
relevance in progression-free survival (PFS). Our data indicate 
that NKp46 inference warrants more investigation and valida-
tion with a larger cohort as well as longer follow-up, as it could 
have prognostic implications.
crc-nK Functionality can Be stimulated 
by immune Therapies
To identify immune strategies to restore CRC-NK functional-
ity, we addressed different in  vitro treatments, including the 
pre-incubation of tumor cells with cetuximab and NK cell 
stimulation with lenalidomide, IL-2, or IL-15. Pre-treatment of 
DLD-1 cells with cetuximab significantly augmented tumor cell 
lysis mediated by CRC-NK (Figure 7A, left panel). Still, ADCC 
response of CRC-NK cells reached lower levels than HD-NK, 
in both early and late stages (Figure 7A, middle panel), prob-
ably due to diminished molecule density of CD16 (FcγR) in 
CRC-NK (Figure 7A, right panel). However, addition of IL-2 
or IL-15 to NK cells completely restored ADCC capacity to 
HD-NK levels (Figure 7B). In this respect, cetuximab combined 
with cytokines allowed CRC-NK to reach normal lytic activity. 
Pre-stimulation with IL-2 or IL-15 modulated several NK cell 
receptors that could contribute to enhance functionality (Figure 
S2 and Table S3 in Supplementary Material). Lenalidomide pre-
treatment did not improve NK cell activity (data not shown). 
Finally, we performed a dynamic lysis assay in which low lytic 
activity due to DNAM-1, NKG2D, and NKp30 blockade was 
reestablished by cetuximab combined with IL-2 pre-stimulation 
(Figure  7C). Cetuximab itself did not have any effect on the 
CI of DLD-1 cells due to their KRAS mutational status (data 
not shown); the antibody acted only through the immune 
pathway. We observed a greater relative increase in functional-
ity of CRC-NK than HD-NK cells in response to cytokines and 
FigUre 4 | nK cell receptors involved in lytic activity. (a) Correlations between NK cell receptor expression and lysis activity against DLD-1 cells from CRC-NK 
(left) and HD-NK (right). Correlations were performed with Spearman or Pearson test. Regression coefficients r and p values on each graph. (B) Upper: 
representative graph of dynamic measurement of DLD-1 cell index vs. time in control conditions (white dots) or with IL-2-activated NK cells from HD (black dots). 
Middle: percentage of DLD-1 cells lysis inhibition using different blocking antibodies against NK cell-activating receptors measured at 300 min (n = 3 independent 
experiments). Percentage of lysis inhibition was calculated as: (% lysis with isotypic control mAb − % lysis with blocking mAb)/% lysis with isotypic control 
mAb × 100. Comparison was performed using one-way ANOVA. Lower: percentage of DLD-1 lysis by IL-2-activated HD-NK cells with isotype mAb control or 
NKp30 blocking mAb. E:T 1:1 NK: DLD-1. *p < 0.05. **p < 0.01.
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mAb joint stimulus (almost fourfold higher), while the relative 
increase in response to independent activation with cytokines 
or cetuximab did not differ between CRC patients and HD 
(Figure S3 in Supplementary Material).
DiscUssiOn
Natural killer cells are major cytotoxic innate immunity players 
against tumor cells in the early immune defense, monitoring 
aberrant ligand expression that usually occurs during malignant 
transformation. The ability of NK cells to rapidly lyse target cells 
without previous immunization could be significant in tumor 
restraint, and their cytokine release may have a strong impact 
on adaptive immunity. Several approaches have recently been 
developed to enhance NK cell antitumor function to prolong 
in vivo survival (after adoptive cell transfer therapy) and promote 
“homing” to the tumor microenvironment, potentially leading 
to improvement in therapeutic outcome (33). Therefore, we 
performed an extensive study of NK cells in CRC patients, with 
the aim of finding a rationale for the development of combined 
NK-based immunotherapies with current treatments. Given 
that colorectal tumor-infiltrating NK cells are scarce and deeply 
deregulated (21, 34), they do not seem to exert a relevant activity 
at tumor site. Nevertheless, circulating NK cells may display a 
role in metastasis control as it has been recently demonstrated 
(35). Impairment of NK cell activity in blood circulation has been 
identified in several human cancers, including breast cancer and 
melanoma, mainly due to defective phenotypic balance between 
activating and inhibitory receptors (36–38). These phenotypic 
alterations exert a negative effect on NK cell functionality and the 
NCR group seems to be the principal regulating pathway (39). 
In particular, Fregni et al. (28) determined that low expression 
of NKp46 in PB NK cells of stage IV melanoma patients was 
associated with a faster progression.
FigUre 6 | nKp46 expression is correlated with relapse-free survival 
of crc patients. (a) Kaplan–Meier curves of CRC patients (n = 52) 
performed as relapse-free survival percentage through time according to 
disease stage (I–IV). (B) Relapse-free survival curves of CRC patients (n = 10 
in each group) according to NKp46 receptor expression by NK cells. Median 
value of NKp46 percentage in CRC population (86.9%) was used as cut-off 
between the two groups.
FigUre 5 | soluble TgF-β is augmented in crc plasma. (a) TGF-β 
concentration (picograms per milliliter) in plasma of CRC patients and HD, 
measured by ELISA (n = 9). (B) TGF-β levels of CRC patients according 
to disease stage (I–II and III–IV). Horizontal bar represents mean value.* 
p < 0.05.
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In this study, we report that NK cells were more abundant 
in PB of CRC patients than in HD, reaching higher values in 
stage IV. This was a surprising finding given that the number of 
circulating NK cells in other malignancies was not found to differ 
from the normal population (28, 39). However, higher percent-
ages and number of NK cells did not correspond to increased 
antitumor activity, as CRC-NK cells displayed an altered expres-
sion of the main activating receptors. While in  most cancers, 
NK cell phenotypic and functional dysregulation was observed 
in tumor-infiltrating NK cells (40–45), only a few PB-NK cells 
receptors were found altered (28, 36, 40, 41). However, CRC-NK 
cells presented a profound disequilibrium with underexpres-
sion of CD16, NKG2D, DNAM-1, NKp30, NKp46, CD161, and 
CD158a and overexpression of the inhibitory receptors CD85j 
and NKG2A. By blocking these receptors in dynamic lysis assays; 
here, we provide evidence for the potential linkage between 
NKp30, NKG2D, and DNAM-1 and NK activity against CRC 
cells. It was previously demonstrated that NCRs and NKG2D can 
trigger a complementary or synergistic response (46); however, in 
our in-vitro setting, NKp30 was the pivotal receptor using DLD-1 
cells as target. This deregulated phenotype and consequent 
functional detriment was present in all clinical stages of disease 
implying an early remodeling of innate immune subsets that 
could favor tumor progression. Meanwhile patients with poorly 
differentiated tumors, which generally indicate a worse outcome, 
displayed higher percentages of NKG2D and DNAM-1 perhaps 
due to tumor additional protection of mucin and alternative 
mechanisms of immune evasion. Conversely, Peng et  al. (22) 
observed that the percentage of NKG2D positively correlated 
with histological grade in CRC (p <  0.01), and they observed 
NKp46 downregulation in stage IV. None of the molecules stud-
ied in that research were associated with blood vessel invasion 
or nerve invasion in CRC. In contrast, we found an association 
between low CD8 expression in NK cell population and tumor 
vascular invasion. It has been suggested that NK cells expressing 
CD8 maintain greater lytic activity as proposed that this subset of 
NK cells could potentially be associated with this clinical feature 
(47, 48).
Colorectal cancer-NK cells challenged with tumor cells pre-
sented decreased IFN-γ production, degranulation, and lysis in 
all stages of disease. This observation contrasts with findings in 
melanoma, lung, and breast cancer patients (28, 36, 38); for whom 
NK cell alterations were higher in advanced metastatic patients. 
Given that downregulation of activating receptors and upregula-
tion of the inhibitory receptors are both present in early stages, it 
is possible that low NK cell functionality prevents NK cells from 
efficiently attacking and eliminating tumor cells in circulation 
at premature and advanced phases of disease. In this regard, it 
would be interesting to evaluate pre-neoplastic colorectal lesions, 
in order to test the hypothesis that an immune system charac-
terized by dysregulated NK cells could be a substrate for tumor 
establishment.
In an exploratory and observational cohort, we demonstrated 
that patients whose NK cells expressed high values of NKp46 
at surgery had statistically longer RFS compared with patients 
presenting low NKp46. This receptor was previously associated 
with progression in stage IV melanoma patients (28). Pagès et al. 
FigUre 7 | crc-nK lysis is restored by cetuximab. (a) Left: percentage of DLD-1 lysis by CRC-NK cells at 2.5:1 E:T ratio assessed by calcein release test in 
presence of an isotype control mAb or Cetuximab (1 μg/ml). Middle: ADCC percentages of CRC patients (n = 16) divided in early (I–II) and late (III–IV) stages. Right: 
CD16 mean fluorescence intensity (MFI) measured in CRC-NK (n = 14) and HD-NK cells. (B) Percentages of DLD-1 cells lysis at 2.5:1 ratio in presence of cetuximab 
(1 μg/ml) by IL-2- (left) or IL-15- (right) pre-stimulated CRC-NK and HD-NK cells. Patients were divided in early (I–II) and late (III–IV) stages. (c) Percentages of DLD-1 
lysis by IL-2-pre-stimulated purified HD-NK cells in presence of isotype antibodies; cetuximab; NKp30, DNAM-1, and NKG2D blocking antibodies; or these blocking 
antibodies plus cetuximab (n = 3 independent experiments). *p < 0.05; ns, non-significant.
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showed that in-situ immune infiltrate was a positive prognostic 
factor for disease evolution and survival (8). Surprisingly, in 
our study, NKp46 was associated with longer RFS in stages I 
to III CRC. More interestingly, this difference continued to be 
statistically significant when stages II and III were analyzed 
independently (data not shown). Of note, most patients in our 
cohort received adjuvant treatment after surgery, many of them 
probably unnecessarily either because they were already cured 
or because they will relapse despite treatment. Currently, clinical 
and pathological variables of disease cannot predict prognosis, 
it is essential to identify patients who will benefit from adjuvant 
therapy; hence, we are planning to confirm these findings in a 
larger, prospective, observational study.
Natural killer cell deregulation may be a consequence of 
soluble factors produced by tumors that promote a systemic 
inhibition without direct contact to the immune cells (31, 
49–55). TGF-β exerts numerous effects on NK cells, including 
the inhibition of cytokine secretion, proliferation, cytotoxicity, 
and the downregulation of activating receptors, such as NKG2D 
and NKp30 (52, 53, 55, 56). TGF-β levels often elevated in 
the sera of cancer patients were associated with inhibition of 
immune function, including weakened NK cell responses, and 
poor prognosis (45, 54, 55). Therefore, the augmentation of 
plasma TGF-β observed in a few patients could be responsible 
for the major dysregulation in CRC-NK from early stages of 
the disease. Further analyses in a higher number of samples 
11
Rocca et al. NK Cells in Colorectal Cancer Patients
Frontiers in Immunology | www.frontiersin.org October 2016 | Volume 7 | Article 413
are needed to better study TGF-β expression and phenotypic/
functional alteration in CRC-NK cells.
In an effort to reach an efficient NK cell status, a combination 
of therapies from early stages of disease could be developed, such 
as stimulation by cytokines and administration of mAbs to facili-
tate ADCC of NK cells. We did not observe any potentiating effect 
by lenalidomide in vitro, an immune-stimulating drug reported 
to activate T lymphocytes to secrete IL-2 that would, at the same 
time, stimulate NK cells (57). However, it would be important to 
study the effect of lenalidomide in in-vivo models.
By targeting EGFR with the antibody cetuximab, administered 
to treat metastatic K-RAS wild-type CRC patients (58), our data 
indicate that exhausted NK cells could be activated in presence 
of IL-2 or IL-15. Currently, several clinical trials are evaluating 
the uses of mAbs and cytokines (NCT02507154, NCT00569296 
and NCT00625729 among others; https://clinicaltrials.gov). 
An alternative therapy that would be interesting to test is the 
administration of anti-TGF-β antibodies, in combination with 
cetuximab and cytokines, to eliminate a possible pathway of 
immunosuppression of CRC tumors.
Considering the recent proof-of-concept published trials 
demonstrating a potential role of anti-PD1 therapies in a subset 
of refractory advanced colorectal carcinoma patients, efforts are 
being done not only to understand the mechanisms in which 
immune cells can modulate CRC progression but also to find 
biomarkers to effectively select the patients that could benefit 
from these new therapeutic approaches. Since NK cell surveil-
lance represents a crucial immune response, investigation of the 
underlying mechanisms for its functional impairment in CRC 
patients would open new strategies for effective treatment focus-
ing on NK cell activity.
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FigUre s1 | gating strategy of nK cell phenotype analysis by Facs. 
Expression of NKp30 and its corresponding Isotype control are shown as 
representative dot plots of thirteen receptors studied.
FigUre s2 | Modulation of activation marker cD69 and natural 
cytotoxicity receptors (ncr) expression on hD-nK cells after overnight 
il-2 or il-15 treatments.
FigUre s3 | crc-nK and hD-nK relative increase in functionality – lysis 
(a) or aDcc (B) – due to il-2 or il-15 stimulation. (c) CRC-NK and HD-NK 
relative increase in lysis due to joint stimulation by cetuximab and IL-2 or IL-15.
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